PL2287180T3 - Pochodne Lol p 5 o zredukowanej alergeniczności i utrzymanej reaktywności dla komórek T - Google Patents
Pochodne Lol p 5 o zredukowanej alergeniczności i utrzymanej reaktywności dla komórek TInfo
- Publication number
- PL2287180T3 PL2287180T3 PL10009856T PL10009856T PL2287180T3 PL 2287180 T3 PL2287180 T3 PL 2287180T3 PL 10009856 T PL10009856 T PL 10009856T PL 10009856 T PL10009856 T PL 10009856T PL 2287180 T3 PL2287180 T3 PL 2287180T3
- Authority
- PL
- Poland
- Prior art keywords
- lol
- conserved
- derivatives
- reactivity
- cell reactivity
- Prior art date
Links
- 230000009257 reactivity Effects 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 abstract 3
- 239000013566 allergen Substances 0.000 abstract 2
- 230000003266 anti-allergic effect Effects 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 241001330029 Pooideae Species 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10325508 | 2003-06-04 | ||
| EP04739147A EP1629006B1 (de) | 2003-06-04 | 2004-05-06 | Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität |
| EP10009856.5A EP2287180B9 (de) | 2003-06-04 | 2004-05-06 | Lol p 5-Derivate mit reduzierter Allergenität und erhaltener T-Zellreaktivität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2287180T3 true PL2287180T3 (pl) | 2013-12-31 |
Family
ID=33494849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10009855T PL2272863T3 (pl) | 2003-06-04 | 2004-05-06 | Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t |
| PL10009856T PL2287180T3 (pl) | 2003-06-04 | 2004-05-06 | Pochodne Lol p 5 o zredukowanej alergeniczności i utrzymanej reaktywności dla komórek T |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10009855T PL2272863T3 (pl) | 2003-06-04 | 2004-05-06 | Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8628946B2 (enExample) |
| EP (3) | EP2272863B1 (enExample) |
| JP (2) | JP4782671B2 (enExample) |
| CN (1) | CN1798763B (enExample) |
| AT (1) | ATE513848T1 (enExample) |
| AU (1) | AU2004245184B2 (enExample) |
| BR (1) | BRPI0410908A (enExample) |
| CA (1) | CA2528053C (enExample) |
| ES (3) | ES2434720T3 (enExample) |
| PL (2) | PL2272863T3 (enExample) |
| PT (3) | PT2287180E (enExample) |
| RU (1) | RU2368620C2 (enExample) |
| WO (1) | WO2004108758A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR779201A0 (en) | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| PT2287180E (pt) * | 2003-06-04 | 2013-10-31 | Merck Patent Gmbh | Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| US9975932B2 (en) | 2010-01-14 | 2018-05-22 | Merck Patent Gmbh | Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues |
| KR20240055084A (ko) | 2021-09-13 | 2024-04-26 | 라이프 테크놀로지스 코포레이션 | 유전자 편집 도구 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736362A (en) * | 1990-10-26 | 1998-04-07 | The University Of Melbourne | Ryegrass pollen allergen |
| DE19713001A1 (de) | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung |
| DE19918682A1 (de) | 1999-04-23 | 2000-10-26 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens |
| IT1318692B1 (it) | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche di phleum pratense. |
| DE60136653D1 (de) * | 2000-11-16 | 2009-01-02 | Alk Abello As | Mutante allergene |
| AUPR779201A0 (en) * | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| PT2287180E (pt) * | 2003-06-04 | 2013-10-31 | Merck Patent Gmbh | Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t |
-
2004
- 2004-05-06 PT PT100098565T patent/PT2287180E/pt unknown
- 2004-05-06 BR BRPI0410908-2A patent/BRPI0410908A/pt not_active IP Right Cessation
- 2004-05-06 ES ES10009856T patent/ES2434720T3/es not_active Expired - Lifetime
- 2004-05-06 PL PL10009855T patent/PL2272863T3/pl unknown
- 2004-05-06 RU RU2005141524/13A patent/RU2368620C2/ru not_active IP Right Cessation
- 2004-05-06 CA CA2528053A patent/CA2528053C/en not_active Expired - Fee Related
- 2004-05-06 US US10/559,272 patent/US8628946B2/en not_active Expired - Fee Related
- 2004-05-06 WO PCT/EP2004/004848 patent/WO2004108758A1/de not_active Ceased
- 2004-05-06 PL PL10009856T patent/PL2287180T3/pl unknown
- 2004-05-06 AU AU2004245184A patent/AU2004245184B2/en not_active Ceased
- 2004-05-06 PT PT04739147T patent/PT1629006E/pt unknown
- 2004-05-06 JP JP2006508164A patent/JP4782671B2/ja not_active Expired - Fee Related
- 2004-05-06 EP EP10009855A patent/EP2272863B1/de not_active Expired - Lifetime
- 2004-05-06 CN CN200480015311XA patent/CN1798763B/zh not_active Expired - Fee Related
- 2004-05-06 ES ES10009855T patent/ES2397778T3/es not_active Expired - Lifetime
- 2004-05-06 AT AT04739147T patent/ATE513848T1/de active
- 2004-05-06 EP EP10009856.5A patent/EP2287180B9/de not_active Expired - Lifetime
- 2004-05-06 ES ES04739147T patent/ES2367633T3/es not_active Expired - Lifetime
- 2004-05-06 PT PT100098557T patent/PT2272863E/pt unknown
- 2004-05-06 EP EP04739147A patent/EP1629006B1/de not_active Expired - Lifetime
-
2010
- 2010-09-16 JP JP2010207438A patent/JP5363441B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-02 US US14/146,364 patent/US9522938B2/en not_active Expired - Fee Related
-
2016
- 2016-04-05 US US15/090,935 patent/US20160207967A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11479605B2 (en) | Homodimeric protein constructs | |
| JP2023515386A (ja) | 制御性ｔ細胞エピトープと脱寛容化ｓａｒｓ－ｃｏｖ－２抗原 | |
| WO2009154995A3 (en) | Interleukin 10 receptor (il-10r) antibodies and methods of use | |
| IN2009CN03372A (enExample) | ||
| MY149128A (en) | A method for the mass production of immunoglobulin fc region deleted initial methionine residues | |
| CA3118981A1 (en) | Immunogenic peptides with improved oxidoreductase motifs | |
| PT2287180E (pt) | Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t | |
| EP1219301B1 (en) | Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins | |
| PT1768996E (pt) | Variantes dos alergénios do grupo 1 das poaceae com alergenecidade reduzida e mantendo a reactividade das células t | |
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| WO2003093416A3 (en) | Protective antigens for the control of ixodes species infestations | |
| BR0312068A (pt) | Sequência de dna e preparação de alérgeno de pólen de gramìneas phl p 4 por métodos recombinantes | |
| WO2013011184A3 (es) | Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes | |
| PL363501A1 (en) | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity | |
| NZ593086A (en) | Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility | |
| WO2004113361A3 (en) | Novel prokineticin receptor isoforms and methods of use | |
| PL2261336T3 (pl) | Sekwencja dna i rekombinacyjne otrzymywanie alergenów głównych grupy 4 ze zbóż | |
| Ågren et al. | A genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit | |
| WO2007042326A3 (en) | Neisseria meningitidis antigens | |
| WO2006058277A3 (en) | Method for identifying and designing immunogenic peptides |